Vaccinex (VCNX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

VCNX Vaccinex

Watchlist

3.2200
+0.1200+3.87%

Close Nov 11 16:00 ET

3.2200
0.00000.00%

Post 20:01 ET

9.00MMarket Cap-813P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Vaccinex Announces Signing Of Proprietary Project Agreements With Amgen, Merck, Chugai, Absci, Gigagen, Merus, Soleil, ThirdArc And Incyte To Employ Vaccinex's ActivMAb Technology
BenzingaNov 7 08:33 ET
Express News | Vaccinex Provides Update on Activmab® Platform: Multiple Project Deals and Presentation at SITC
ReutersNov 7 08:30 ET
Vaccinex Provides Update on ActivMAb Platform: Multiple Project Deals and Presentation at SITC
GlobeNewswireNov 7 08:30 ET
Vaccinex to Preset New Biomarker Data on HNSCC
TipRanksNov 5 08:40 ET
Vaccinex Reports Improved Immunity Correlating With Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting
GlobeNewswireNov 5 08:30 ET
Express News | Vaccinex Reports Improved Immunity Correlating With Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
ReutersNov 5 08:30 ET

Comments

Jaguar8

Nov 7 07:31

NEWS

$Vaccinex (VCNX.US)$
Vaccinex Provides Update on Activmab® Platform: Multiple Project Deals and Presentation at SITC
Vaccinex (NASDAQ: VCNX) announced multiple proprietary project agreements with major pharmaceutical companies including Amgen, Merck, Chugai, and others for using its ActivMAb® technology platform. The technology enables expression of complex proteins for antibody discovery, particularly useful for developing immunotherapies. The company will also provide materials to strategic...

Jaguar8

Nov 5 07:31

NEWS

$Vaccinex (VCNX.US)$
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

Yuzuru0

Oct 31 17:20

$Vaccinex (VCNX.US)$ why bleeding so bad tho

Jaguar8

Oct 31 12:53

NEWS

$Vaccinex (VCNX.US)$
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain
Vaccinex (VCNX) announced new findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's disease. The study revealed that pepinemab treatment inhibits the expression of plasma GFAP and p-tau 217 biomarkers during Mild Cognitive Impairment (MCI). The treatment showed promising trends in slowing cogni...